Article
Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Journal of medical case reports - 2 Jun 2016
Casadevall David, Vidal Joana, Gallardo Fernando, Zuccarino Flavio, Arumí-Uría Montserrat, Dalmases Alba, Bellosillo Beatriz, Montagut Clara
Abstract excerpt
BACKGROUND: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90-95 % of mutations are either BRAF (V600E) or BRAF (V600K). Specific BRAF inhibitors such as dabrafenib and vemurafenib are the mainstays of treatment in patients with metastatic BRAF-mutant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.